| 恩度联合FOLFOX4方案治疗晚期结肠癌、直肠癌的多中心临床研究 |
| |
| 引用本文： | 周彤,徐建忠,李苏宜,童建东,顾明,王琼,茅卫东,凌扬.恩度联合FOLFOX4方案治疗晚期结肠癌、直肠癌的多中心临床研究[J].江苏临床医学杂志,2012(5):26-28. |
| |
| 作者姓名： | 周彤 徐建忠 李苏宜 童建东 顾明 王琼 茅卫东 凌扬 |
| |
| 作者单位： | [1]苏州大学附属常州肿瘤医院肿瘤内科,江苏常州213000 [2]东南大学附属中大医院肿瘤科,江苏南京210009 [3]东南大学附属扬州市人民医院肿瘤内科,江苏扬州225001 [4]东南大学附属盐城第三人民医院肿瘤内科,江苏盐城224000 [5]东南大学附属江阴人民医院肿瘤科,214400 |
| |
| 基金项目： | 中国高校医学期刊临床专项资金（11220018） |
| |
| 摘 要： | 目的评价重组人血管内皮抑素（恩度）联合FOLFOX4方案治疗晚期结肠癌、直肠癌的有效性和安全性。方法 2006年7月~2010年12月,58例晚期结肠癌、直肠癌患者接受恩度联合FOLFOX4方案：恩度7.5 mg/m2第1~7天,草酸铂85 mg/m2,静滴2 h,第1天;醛氢叶酸200 mg/m2,第1、2天;5-氟尿嘧啶（5-Fu）400 mg/m2,静推,第1、2天;5-Fu600 mg/m2,静滴22 h,第1、2天。2周重复,至少4周期。结果 17例获部分缓解,24例获病情稳定,总有效率为29.3%,临床受益率为70.7%,中位疾病进展时间（TTP）为8.6月,主要毒副反应为中性粒细胞减少（50.0%）,恶心/呕吐（39.7%）,神经毒性（39.7%）。结论恩度联合FOLFOX4方案治疗晚期结肠癌、直肠癌疗效确切,毒副反应可耐受。
|
| 关 键 词： | 恩度 草酸铂 5-Fu 醛氢叶酸 晚期结肠癌、直肠癌 |
Multicenter clinical study on endostar combined with FOLFOX4 in the treatment of advanced colorectal cancer |
| |
| ZHOU Tong,XU Jian-zhong,LI Su-yi,TONG Jian-dong,GU Ming,WANG Qiong,MAO Wei-dong,LING Yang.Multicenter clinical study on endostar combined with FOLFOX4 in the treatment of advanced colorectal cancer[J].Journal of Jiangsu Clinical Medicine,2012(5):26-28. |
| |
| Authors: | ZHOU Tong XU Jian-zhong LI Su-yi TONG Jian-dong GU Ming WANG Qiong MAO Wei-dong LING Yang |
| |
| Institution: | 1.Changzhou Tumor Hospital Affiliated to Soochou University,Changzhou,Jiangsu,213000;2.Zhongda Hospital Affiliated to Southeast University,Nanjing,Jiangsu,210009;3.Yangzhou People′s Hospital Affiliated to Southeast University,Yangzhou,Jiangsu,225001;4.Yancheng No.3 People′s Hospital Affiliated to Southeast University,Yancheng,Jiangsu,224000;5.Jiangyin People′s Hospital Affiliated to Southeast University,Jiangyin,Jiangsu,214400) |
| |
| Abstract: | Objective To investigate the efficacy and safety of endostar combined with FOLFOX4 in advanced colorectal cancer.Methods From July 2006 to December 2010,58 patients with advanced colorectal cancer were administered with endostar combined with FOLFOX4（endostar 7.5 mg/m2,d1 to d7;L-OHP 85 mg/m2,civ,2 h,d1;CF 200 mg/m2,d1,2;5-Fu 400 mg/m2,iv, d1,2;5-Fu 600 mg/m2,civ,22 h,d1,2） for at least 4 cycles.Results Of the 58 patients,17 had partial response（PR）,24 had stable disease（SD）.Median time to progression（TTP） was 8.6 months.Main toxicities were neutropaenia（50.0%）,nausea/vomiting（39.7%） and neuropathy（39.7%）.Conclusion Endostar combined FOLFOX4 is effective and tolerable in the treatment of advanced colorectal cancer. |
| |
| Keywords: | endostar oxaliplatin 5-flurourocil leucovorin advanced colorectal cancer |
| 本文献已被 维普 等数据库收录！ |
|
